Nabi Seeking StaphVAX Indication For All At-Risk Groups; BLA By End Of 2005
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nabi is initiating immunogenicity trials of its S. aureus vaccine StaphVAX in new patient groups in hopes of securing a broad approval for use in all at-risk adults.
You may also be interested in...
Nabi Discontinues StaphVax After Confirmatory Phase III Trial Fails
Nabi Biopharmaceuticals is halting development of its Staphylococcus aureus vaccine StaphVax after the product's failure to show efficacy in a 3,600-patient confirmatory trial
Nabi revises StaphVax study
Nabi will increase the number of end-stage renal disease patients in a confirmatory Phase III trial of its Staphylococcus aureus vaccine, StaphVax, from 3,000 to 3,600. "The decision to expand the sample size was made following additional dialogue with FDA as to what would constitute a meaningful effect in the context of the adverse event profile," the company says. The larger patient population will power the study to show statistical significance with a clinical reduction of 50% or more in S. aureus infections through eight months post-vaccination; the initial Phase III study showed significant results through 10 months at a 60% reduction rate. The company estimates approximately 12 mil. U.S. patients are at risk of contracting an S. aureus infection. Nabi plans to submit an NDA by the end of 2005...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011